Aspartic Acid

Aspartic Acid

SCHEMBL693370

NC(CC(=O)[O-])C(=O)[O-].NC(CC(=O)[O-])C(=O)[O-].NC(CC(=O)[O-])C(=O)[O-].[Fe+3].[Fe+3]

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC6A2SLC6A3SSTR1SSTR2SSTR3SSTR5

The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CA4 P22748 4/20 0.48
CTSL P07711 1/20 0.44
CPT2 P23786 1/20 0.43
CPT1A P50416 1/20 0.43
CA2 P00918 1/20 0.42
SLC22A16 Q86VW1 1/20 0.36
GRIK1 P39086 1/20 0.31
GRIK2 Q13002 1/20 0.31
GRM1 Q13255 1/20 0.31
GRM2 Q14416 1/20 0.31
GSR P00390 1/20 0.31
PTGS1 P23219 1/20 0.31
SLC7A11 Q9UPY5 1/20 0.31
CASP1 P29466 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aspartic Acid SCHEMBL518280 0.94 CA4 (0.48) CA4CTSLCPT2CPT1ACA2
Aspartic Acid SCHEMBL161238 0.94 CA4 (0.48) CA4CTSLCPT2CPT1ACA2
Aspartic Acid SCHEMBL20400343 0.94 CA4 (0.48) CA4CTSLCPT2CPT1ACA2
Aspartic Acid SCHEMBL11903448 0.94 CA4 (0.48) CA4CTSLCPT2CPT1ACA2
Aspartic Acid SCHEMBL7635443 0.94 CA4 (0.48) CA4CTSLCPT2CPT1ACA2
Aspartic Acid SCHEMBL120390 0.94 CA4 (0.52) CA4CTSLCPT2CPT1ACA2
Aspartic Acid SCHEMBL1655126 0.94 CA4 (0.48) CA4CTSLCPT2CPT1ACA2
Aspartic Acid SCHEMBL21054602 0.94 CA4 (0.52) CA4CTSLCPT2CPT1ACA2
Aspartic Acid SCHEMBL22401093 0.94 CA4 (0.52) CA4CTSLCPT2CPT1ACA2
Aspartic Acid SCHEMBL16431397 0.94 CA4 (0.48) CA4CTSLCPT2CPT1ACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115463124-B Iron supplementing effervescent tablet and preparation method thereof 海而思(郑州)科技有限公司 2024-04-05 CN claimed
CN-115463124-A Iron-supplementing effervescent tablet and preparation method thereof 海而思(郑州)科技有限公司 2022-12-13 CN claimed
CN-113317428-A Calcium, iron and zinc solid preparation and preparation method thereof 海而思(郑州)科技有限公司 2021-08-31 CN claimed
WO-2021137780-A1 PREPARATION OF FILM TABLET COMPOSITION COMPRISING HEME IRON FOR IRON DEFICIENCY İLKO İLAÇ SANAYİ VE TİCARET A.Ş. (TR) 2021-07-08 WO claimed
EP-3216782-B1 IRON AMINO ACID COMPOUNDS, METHOD FOR PREPARING IRON AMINO ACID COMPOUNDS, COMPOSITIONS CONTAINING IRON AMINO ACID COMPOUNDS, AND USES THEREOF NPA NUCLEO DE PESQUISAS APLICADAS LTDA (BR) 2021-06-02 EP claimed
US-20210122705-A1 IRON AMINO ACID COMPOUNDS, METHOD FOR PREPARING IRON AMINO ACID COMPOUNDS, COMPOSITIONS CONTAINING IRON AMINO ACID COMPOUNDS, AND USES THEREOF NPA NUCLEO DE PESQUISAS APLICADAS LTDA (BR) 2021-04-29 US claimed
US-20180370903-A1 IRON AMINO ACID COMPOUNDS, METHOD FOR PREPARING IRON AMINO ACID COMPOUNDS, COMPOSITIONS CONTAINING IRON AMINO ACID COMPOUNDS, AND USES THEREOF NPA - NÚCLEO DE PESQUISAS APLICADAS LTDA. (BR) 2018-12-27 US claimed
US-9913806-B2 Patches and methods for the transdermal delivery of a therapeutically effective amount of iron FE3 MEDICAL, INC. (US) 2018-03-13 US claimed
EP-3216782-A1 IRON AMINO ACID COMPOUNDS, METHOD FOR PREPARING IRON AMINO ACID COMPOUNDS, COMPOSITIONS CONTAINING IRON AMINO ACID COMPOUNDS, AND USES THEREOF NPA - Núcleo De Pesquisas Aplicadas LTDA. (BR) 2017-09-13 EP claimed
US-9731982-B2 Surface modified ceramic filter UNIVERSITY OF KANSAS (US) 2017-08-15 US claimed
EP-2421601-A2 METHOD FOR TRANSDERMAL IONTOPHORETIC DELIVERY OF CHELATED AGENTS Incube Labs, Llc (US) 2012-02-29 EP claimed
WO-2010123584-A2 METHOD FOR TRANSDERMAL IONTOPHORETIC DELIVERY OF CHELATED AGENTS INCUBE LABS, LLC (US) 2010-10-28 WO claimed
US-20090035385-A1 COMPOSITIONS INCLUDING IRON DRUGTECH CORPORATION (US) 2009-02-05 US claimed
EP-1827418-A2 COMPOSITIONS INCLUDING IRON Drugtech Corporation (US) 2007-09-05 EP claimed
EP-1827419-A2 METHODS AND COMPOSITIONS FOR ENHANCING IRON ABSORPTION Drugtech Corporation (US) 2007-09-05 EP claimed
WO-2006068697-A2 COMPOSITIONS INCLUDING IRON DRUGTECH CORPORATION (US) 2006-06-29 WO claimed
WO-2006068729-A2 METHODS AND COMPOSITIONS FOR ENHANCING IRON ABSORPTION DRUGTECH CORPORATION (US) 2006-06-29 WO claimed
US-20060134227-A1 Compositions including iron DRUGTECH CORPORATION 2006-06-22 US claimed
WO-2003086321-A2 MODIFIED RELEASE MINERALS DRUGTECH CORPORATION (US) 2003-10-23 WO claimed
US-20030190355-A1 Modified release minerals DRUGTECH CORPORATION 2003-10-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210122705-A1 IRON AMINO ACID COMPOUNDS, METHOD FOR PREPARING IRON AMINO ACID COMPOUNDS, COMPOSITIONS CONTAINING IRON AMINO ACID COMPOUNDS, AND USES THEREOF HAMP, FECH, TFRC CA4 1390/4885CTSL 3461/4885CPT2 1273/4885
US-20180370903-A1 IRON AMINO ACID COMPOUNDS, METHOD FOR PREPARING IRON AMINO ACID COMPOUNDS, COMPOSITIONS CONTAINING IRON AMINO ACID COMPOUNDS, AND USES THEREOF HAMP, FECH, TFRC CA4 1390/4885CTSL 3461/4885CPT2 1273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.